Detalles del proyecto

Coste total:

Aportación de la UE:

Coordinado en:

Tema(s):

Régimen de financiación:

CSC - Cost-sharing contracts

Objetivo

The main goal of this proposal is to develop, produce and validate a cell-based targeted therapeutic delivery system comprising cells encapsulated in an ultra pure alginate gel. Cell lines will be developed which produce tumour growth inhibitory substances such as antiangiogenic proteins (endostatin, angiostatin) as well as antibodies to cancer cell growth receptors. The encapsulated cell prototype will be evaluated for efficacy against brain tumours, for which there is no adequate treatment today. An ultra pure alginate will be developed and characterised which will meet regulatory standards for implantation into the brain. The final step in the proposal is to document the preclinical efficacy of this alginate encapsulated cell therapy towards brain tumours in small animal models such as rats and in spontaneously occurring brain tumours in dogs.